Antitrust & Trade Reg.
Sep. 5, 2023
FTC ends block to Amgen merger, settles claims
Amgen said it is disappointed by the FTC’s decision to file the claims, denied wrongdoing, and said it remains committed to completing the acquisition of its acquisition of Horizon Therapeutics in Ireland.
California has joined a settlement addressing claims of antitrust violations by pharmaceutical giant Amgen Inc. as the Federal Trade Commission ended its bid to block the company’s proposed $28 billion acquisition of another drug manufacturer.
The settlement does not constitute an admission that the law has been violated, filed documents said.
“The California Department of Justice has for years called on the FTC...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In